About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, December 8th, 2017

The QualityStocks
Daily Stock List


ImageWare Systems, Inc. (IWSY)

Pennybuster, PennyStocks24, Wall Street Daily, Wall Street Resources, Greenbackers, Microcapmillionaires, and TaglichBrothers reported earlier on ImageWare Systems, Inc. (IWSY), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc. is a foremost developer of mobile and cloud-based multi-modal biometric identity management solutions, providing biometric, secure credential, and also law enforcement technologies. The Company’s biometric product line is scalable for worldwide deployment. Listed on the OTC Markets’ OTCQB, ImageWare Systems is headquartered in San Diego, California.

The Company’s biometric product line includes a multi-biometric engine. This engine is hardware and algorithm independent. This permits the enrolment and management of unlimited population sizes.

ImageWare’s identification products are used to manage and issue secure credentials. This includes national IDs, passports, driver's licenses, smart cards, and access control credentials. Its digital booking products provide law enforcement with integrated mug shot, fingerprint livescan, and investigative capabilities.

ImageWare has its GoCloudID.com. GoCloudID.com is a highly modular, SOA-based software platform. It delivers a first-rate capability to quickly develop and deploy highly secure, yet flexible standards based identity solutions.

The Company has its EPI Builder®. This provides the underpinning for a multi-modal biometric capture platform, which ensures device interoperability and support for centralized and distributed deployment models. Additionally, products include IWS Biometric Engine®. This is the first and only truly multi-modal, device-and algorithm-independent biometric software platform.

ImageWare Systems’ next-generation cloud identity management and authentication service is GoMobile Interactive™ (GMI). GMI is a cloud-based, multi-modal biometric mobile identity management solution. GMI is built upon the award-winning IWS Biometric Engine® (IWS BE), an SOA based server platform that enables advanced biometric data process and management with ESB connectivity.

ImageWare also has its GoVerifyID solution. GoVerifyID is its patented mobile biometric user authentication solution. The Company also has its GoVerifyID® Enterprise Suite. This is an innovative, multi-modal, multi-factor biometric authentication solution for the enterprise market.

GoVerifyID Enterprise Suite is an algorithm-agnostic solution. It is the first ever end-to-end biometric platform that seamlessly integrates with an enterprise's existing Microsoft infrastructure. This provides businesses a turnkey biometric solution for fast deployment in an afternoon or less.

ImageWare delivers inventive mobile capabilities to the wireless, financial services, and healthcare sectors. The pillphone® enabled by the Company’s GoMobile interactive push application platform, is Food and Drug Administration (FDA) cleared. It is the only mobile health management application secured by biometrics.

ImageWare Systems and Secure Channels, Inc. (SCI) are enhancing the world’s first Entertainment Security Operations Center with multi-factor biometric authentication. Secure Channels’ ESOC is the world’s first members’ only, closed end, centralized ecosystem for secure management of the entertainment industry’s chain-of-custody, content and intellectual property (IP). Therefore, this provides member clients with an automated architecture.

Coupled with ImageWare Systems’ GoVerifyID biometric identity management solution, it produces a seamless, secure method for authorizing, accessing, and administering valuable entertainment-related, work-in-process content. Secure Channels is a provider of unique security solutions designed to complement existing security investments.

GoVerifyID for IBM Security Access Manager (ISAM) is now available on the IBM Security App Exchange. GoVerifyID seamlessly integrates with IBM identity and access management technology. This is to provide a flexible, end-to-end, multi-modal, biometric security solution for all ISAM authentication processes.

ImageWare Systems, Inc. (IWSY), closed Friday's trading session at $1.40, down 2.10%, on 52,164 volume with 49 trades. The average volume for the last 60 days is 108,025 and the stock's 52-week low/high is $0.8117/$1.62.

Namaste Technologies, Inc. (NXTTF)

Stockhouse, OTC Markets, MarketWatch, InvestorsHub, InvestorsHangout, TradingView, and Daily Marijuana Observer reported on Namaste Technologies, Inc. (NXTTF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Namaste Technologies, Inc. is the largest online retailer for medical cannabis delivery systems around the world. The Company distributes vaporizers and smoking accessories via e-commerce sites in 26 countries and with 5 distribution hubs located internationally. Namaste’s long term strategy is to become a foremost supplier of legal cannabis products as the cannabis market is legalized in each nation. Namaste Technologies has its corporate office in Toronto, Ontario. Its U.S. office is in Jupiter, Florida and its Bahamas office is in Lyford Cay.

The Company owns and operates online retail sites with a presence in numerous countries. Namaste Technologies is a worldwide leader in delivery systems for dry herbs that can include medicinal cannabis where legally available. Through vaporizer sales and the selling of glass and pipes and other dry herb related paraphilia, Namaste has a very strong channel to sell to end consumes once it is legalized globally.

In addition, Namaste is active in product development and manufacturing. It will launch the Grizzly Eclipse Vaporizer soon. The Company is in the final stages of its Cannmart license to gain approval to distribute cannabis in Canada. Legalization is in the final stages in Canada.

Last month, Namaste Technologies announced that it signed a stock purchase agreement with ESC Hughes Holdings Limited to sell the Company’s wholly-owned U.S. subsidiary, Dollinger Enterprises US, Inc. This Agreement includes the sale of the domain names Everyonedoesit.com and NamasteVapes.com that combined represent less than 7 percent of Namaste Technologies’ current gross revenue.

This week, Namaste Technologies announced that it signed a non-binding Letter of Intent (LOI) with O Cannabis We Stand On Guard For Thee. O Cannabis will provide patient consultation services to Namaste’s wholly-owned subsidiary, NamasteMD, Inc.

With this LOI, O Cannabis will provide management services to NamasteMD. This will include patient consultations, education, strain recommendations and medical document issuance to qualified patients under the guidance of nurse practitioners.

Furthermore, O Cannabis will offer a select range of Namaste Technologies’ vaporizer hardware in its online platform. O Cannabis offers affordable medical cannabis telemedicine appointments to patients throughout Canada.

Yesterday, Namaste Technologies announced record breaking sales for the month of November 2017, as reported by Namaste (including shipping revenues after discounts and refunds) of C$2.2M, equating to a 69 percent month-on-month increase and a 146 percent year-on year increase. This represents the Company’s highest month of revenue in its history.

Namaste has acquired the above-mentioned Cannmart, Inc. This is a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program). Via Cannmart, Namaste Technologies is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market.

Namaste Technologies has majority market share in Europe and Australia. The Company has operations in the United Kingdom, the United States, Canada and Germany. Moreover, it has opened new supply channels into developing markets. This includes Brazil, Mexico, and Chile.

Namaste Technologies, Inc. (NXTTF), closed Friday's trading session at $0.73, up 2.70%, on 784,345 volume with 345 trades. The average volume for the last 60 days is 675,547 and the stock's 52-week low/high is $0.124/$1.066.

ZIVO Bioscience, Inc. (ZIVO)

Ceocast News and RedChip reported previously on ZIVO Bioscience, Inc. (ZIVO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ZIVO Bioscience, Inc.’s commitment is to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains. In addition, the Company engages in the development of natural bioactive compounds for use as dietary supplements and food ingredients, and biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

ZIVO Bioscience is re-inventing itself as a licensor of internally developed intellectual property (IP) that includes its proprietary algae cultures, in addition to IP secured by way of strategic acquisitions.

ZIVO Bioscience is headquartered in Keego Harbor, Michigan. Its wholly-owned subsidiary is WellMetris, LLC. ZIVO Bioscience’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s commitment is to the ideal of promoting health through using naturally occurring bioactive agents. These active ingredients are produced and processed to obtain the highest possible efficacy.

ZIVO Bioscience’s works to completely harness the beneficial effects of its natural bioactive agents and make them affordable and readily available in a useful and convenient form. ZIVO has more recently continued to focus almost exclusively on dairy cow applications for its proprietary algal biomass, extracts and any high-value bioactive compounds thereof. This is while developing the business case and production scale-up to cultivate and productize the algal biomass.

ZIVO Bioscience announced earlier in 2017 that it entered into a tolling agreement and technical services contract with Synthetic Genomics, Inc., (SGI) based in La Jolla, California. ZIVO engaged SGI to produce biomass in sufficient quantity to satisfy the sample production demands for validation in an array of compliance studies and tests. These tests and studies have grown in number and scope since late April 2016 as ZIVO scaled up production to establish and test the parameters of commercialization.

This past September, ZIVO Bioscience announced that it began work on the final, primary phase of its discovery-stage bovine mastitis efficacy study. This latest efficacy trial is the final phase of a multi-phased validation effort that started in mid-2014.

ZIVO and an international animal health company entered into an option/collaboration agreement in December 2013 to ascertain if the Company’s bioactive compounds exhibit efficacy in addressing bovine mastitis and analytics to isolate and characterize such bioactive compounds to the satisfaction of the collaborator. Bovine mastitis is a common condition afflicting dairy cows that results in milk production losses.

Furthermore, in September, ZIVO Bioscience announced results from two poultry studies designed and supervised by animal nutrition strategic partner NutriQuest, LLC. The two studies, centered on broiler production, provided encouraging results on the benefits of including a proprietary strain of dried algal biomass in broiler feed under a number of real-world challenges. This development advances the prospective market entry of a ZIVO phytogenic feed ingredient for poultry applications. NutriQuest is a leader in animal health and nutrition solutions.

ZIVO’s core IP consists of the algae culture itself, the patented process of producing that culture, and the bioactive compounds or molecules that can be extracted, and also the application of that culture or extract in supporting health maintenance and longevity. The Company’s plan is to approach the near-term markets first: animal applications, human food ingredients and human dietary supplements. This is while laying the foundation for the more complex and longer-term opportunities in the medicinal and pharmaceutical market verticals.

ZIVO Bioscience, Inc. (ZIVO), closed Friday's trading session at $0.1067, down 2.82%, on 205,869 volume with 16 trades. The average volume for the last 60 days is 76,067 and the stock's 52-week low/high is $0.0502/$0.1469.

eCobalt Solutions, Inc. (ECSIF)

InvestorsHub and MarketWatch reported on eCobalt Solutions, Inc. (ECSIF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

eCobalt Solutions, Inc. explores for mineral properties in the United States and Canada. The Company’s chief asset is the 100 percent owned Idaho Cobalt Project (ICP). This Project remains the sole, advanced stage, near term, environmentally permitted, primary cobalt deposit in the United States.

The Company previously went by the name Formation Metals, Inc. It changed its name to eCobalt Solutions, Inc. in August of 2016. Formed in 1988, eCobalt Solutions is based in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

eCobalt’s rebranding accurately reflects the current and future direction of the Company as a strong player in the renewable energy and electric vehicle sectors. The Company’s commitment is to provide a distinct opportunity for consumers to acquire an ethically sourced, environmentally sound, transparent supply of battery grade cobalt salts, secured safely and responsibly in the United States. Battery grade cobalt salts are vital for the fast-growing rechargeable battery and renewable energy sectors.

eCobalt Solutions’ Idaho Cobalt Project (ICP) consists of the Mine /ill (M&M) site in Lemhi County, Idaho, near the town of Salmon, Idaho, and also the Cobalt Production Facility (CPF). CPF is a stand-alone hydrometallurgical facility expected to be in Southern Idaho.

The ICP is fully permitted. It received a final Environmental Impact Statement and positive Records of Decision from the U.S. Department of Agriculture National Forest Service and the U.S. Environmental Protection Agency (EPA).

The CPF will process concentrates from the M&M into cobalt, copper, and gold end products. The project is scheduled to produce the equivalent of 1,500 tons of high purity cobalt per year over a projected mine life of 12.5 years.

A Feasibility Study (FS) on the ICP completed in 2008. It allowed eCobalt Solutions to fund the initial construction of the project. So far, about 90 percent of the earthworks have been completed at the mine site.

Yesterday, eCobalt Solutions reported that considerable progress has been made to date on optimization of the Idaho Cobalt Project (ICP). This has resulted in a new direction to produce a clean (low arsenic content) cobalt concentrate product. This is an upstream precursor material for battery cathode production, which may result in material reduction of capital and operating cost at the CPF.

Mr. Paul Farquharson, President and Chief Executive Officer of eCobalt Solutions’, said, "Consolidation of battery materials manufacturing in China to decrease cost and increase production capacity has reduced the premium in the price of cobalt sulphate over cobalt metal. Due to these changing battery market dynamics, and in response to discussions with numerous potential offtake parties, the Company has determined that delivering a clean cobalt concentrate product is the fastest route to production, generation of cash-flows and reduction of price and technical risk to the project.”

eCobalt Solutions, Inc. (ECSIF), closed Friday's trading session at $1.088, down 0.19%, on 371,786 volume with 262 trades. The average volume for the last 60 days is 229,153 and the stock's 52-week low/high is $0.355/$1.22.

Fortem Resources, Inc. (FTMR)

OTC Markets, Stockhouse, Stockopedia, and InvestorsHub reported on Fortem Resources, Inc. (FTMR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fortem Resources, Inc. is an oil and gas production, development, and exploration enterprise listed on the OTC Markets Group’s OTCQB. The Company has a diversified natural resource portfolio of primarily oil and gas assets and one gold asset. Fortem Resources has offices in Calgary, Alberta, and North Orem, Utah. The company previously went by the name Strongbow Resources, Inc. It changed its name to Fortem Resources Inc. in March of this year.

Fortem Resources’ properties are situated in Western Canada, North America, and worldwide by way of five wholly-owned subsidiaries. These subsidiaries are Rolling Rock Resources, Black Dragon Energy, Colony Energy, Big Lake Energy, and City of Gold.

The Company’s present operating and technical team has proven success in conventional and non-conventional oil and gas plays in North America and globally. Fortem Resources’ strategy is centered on developing quality energy projects with lower risk profiles and identified upside potential.

In May of this year, Fortem Resources announced that on May 17, 2017, the Company acquired 100 percent of the membership interest in City of Gold, LLC, a Nevada limited liability company, from two Nevada limited liability companies -- MAB Resources Holdings LLC and JM Magna Holdings LLC, pursuant to a Membership Interest Purchase Agreement dated as of May 17, 2017.

With the Option Agreement, Asia Pacific and Nyi Nyi Lwin agreed to grant to City of Gold the option to purchase 100 percent of the ownership interest in a wholly-owned subsidiary of Asia Pacific which, in turn, owns 100 percent of the rights to the City of Gold mineral exploration project in Myanmar that encompasses an area of roughly 465 square kilometers in close proximity to hydropower, water, and infrastructure. This is to accommodate exploration and development of the property. City of Gold can earn the Option upon issuance of an exploration license for the City of Gold Project, subject to a financing condition.

This past August, Fortem Resources announced that it indirectly acquired via Rolling Rock Resources, LLC, a wholly-owned subsidiary, an undivided 75 percent interest in more oil and gas leases in the Mancos formation encompassing a total of 2,313.09 acres. These leases were acquired at a SITLA (State of Utah School and Institutional Trust Lands Administration) auction.

Pursuant to an agreement entered into with Rockies Standard Oil Company, LLC, who holds the remaining 25 percent interest, the parties agreed to enter into a joint operating agreement covering the new leases. These leases are outside the AMI (Area of Mutual Interest) of its original joint venture (JV) lease holdings.

Furthermore, in August, Fortem shared some news about a recent discovery made by BP PLC in the Mancos shale play. The San Juan Basin produces gas from the Mancos shale. This occurs from the center of the basin and transitions into oil around the rims of the basin.

Similar to Fortem Resources’ Mancos area, the oil prone areas have resulted in successful vertical wells where a maximum amount of flexure provides natural fracturing. This permits vertical wells to encounter these fractures to produce considerable amounts of hydrocarbons. Recent horizontal drilling in porosity zones within the Mancos shale has proven to be very productive.

Fortem Resources, Inc. (FTMR), closed Friday's trading session at $2.50, even for the day, on 1,386 volume with 6 trades. The average volume for the last 60 days is 2,297 and the stock's 52-week low/high is $0.25/$3.25.

Almost Never Films, Inc. (HLWD)

The Street, YCharts, MarketWatch, and Marketbeat reported on Almost Never Films, Inc. (HLWD), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Almost Never Films, Inc. is an independent film company based in Los Angeles, California. Its emphasis is on film production and production related services in connection with production costs in the $5.0 million to $50.0 million range. The Company’s business is to enable relationships between creative talent and companies who produce, finance, and distribute motion pictures. Almost Never Films lists on the OTC Markets.

The Company’s intention is to create, acquire, or license rights to materials upon which it believes motion pictures can be based. Mr. Danny Chan is the Chief Executive Officer (CEO) of Almost Never Films. He is also a Managing Director of Iconic Private Equity Partners, headquartered in Hong Kong. Mr. Chan has spent more than 11 years investing and advising Greater China companies.

Almost Never Films and Saisam Entertainment are partnering to develop and produce the motion picture project "Love Is Not Easy." Danny Chan, Frank Gillen, and Brian Hooks, President of Saisam Entertainment, will serve as lead producers of the film. Brian Hooks will also be engaged as the writer and director of the movie.

Almost Never Films will make financial contributions and participate in the development and production process to make the movie a box office success. Saisam Entertainment will contribute its development and producing services and the original screenplay.

Almost Never Films announced this past June that it provided a portion of bridge financing via The Money Pool and Blue Rider San Juan for the feature film “Ana.” The film stars Dafne Keen who earlier appeared in “Logan” with Hugh Jackman.

Almost Never Films also announced in June that it agreed to provide a portion of Bridge financing via The Money Pool and Blue Rider San Juan, for the motion picture “Speed Kills.” The movie will be directed by John Luessenhop. He previously directed Texas Chainsaw 3D and Takers. “Speed Kills” follows the life of speedboat racing champion Don Aronow played by John Travolta.

Last month, Almost Never Films announced that it entered into a strategic partnership with Pure Flix Entertainment. The new partnership is a multi-film financing agreement to produce six faith-based original motion pictures. Pure Flix Entertainment is an American independent Christian film and television studio, based in Scottsdale, Arizona.

Almost Never Films will contribute its financial, development, as well as production services. Pure Flix Entertainment will distribute the films internationally in new media format.

Today, Almost Never Films announced it is teaming with Howard and Karen Baldwin of KEMB PRODUCTIONS, Stuart Benjamin Productions, and Mr. Nick Cassavetes to develop a scripted television series. Mr. Cassavetes will write the pilot. He is also attached to direct the television series.

The pilot follows the rise and fall of Mr. Bruce McNall, a self-made tycoon who owned the Los Angeles Kings of the National Hockey League (NHL). He was also heavily involved in the high profile worlds of antiquities, coins, race horses, film, and sports.

Almost Never Films, Inc. (HLWD), closed Friday's trading session at $1.47, up 19.51%, on 1,200 volume with 8,790 trades. The average volume for the last 60 days is 4,128 and the stock's 52-week low/high is $0.40/$4.00.

GB Sciences, Inc. (GBLX)

Tip.us, Whisper from Wall Street, Wall St Report, CFN Media Group, AllPennyStocks, Stockgoodies, SmallCapVoice, Cannabis Financial Network News, Money Morning, SeriousTraders, Otcstockexchange, PennyStockInformer, StocksToBuyNow, PennyStockLaboratory, Wall Street Resources, Pumps and Dumps, and TradeThesePicks reported earlier on GB Sciences, Inc. (GBLX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

GB Sciences, Inc. is a biopharmaceutical Research and Development (R&D) company. Its focus is on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target an array of medical conditions. GB Sciences’ R&D team is pursuing new formulations derived from specific strains of cannabis, creating patented formulations that will help patients. GB Sciences is based in Las Vegas, Nevada. The Company lists on OTCQB.

GB Sciences provides clean, reliable raw materials for manifold cannabis products and research initiatives. It is creating novel formulations and seeking patents for treatments that will directly assist patients.

GB Sciences announced earlier this year the initial harvest at its Cultivation Lab facility in Las Vegas. When fully operational, Cultivation Lab will contain 7,200 cannabis plants under 600 grow lights within its 28,000 ft. The expectation is that Cultivation Lab will produce about $10 million in annual revenue.

The chief directive of GB Sciences since its inception has been the creation of a quality controlled cannabis cultivation and extraction facility to provide the compounds for formulating medicines to treat a wide assortment of diseases.

The Company has added its own medical-grade retail brand to its portfolio. This portfolio includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.

GB Sciences and Cura Cannabis Solutions have executed a production agreement to produce high quality cannabis oils and related products using the GB Sciences production license operated by the GB Sciences' Cultivation Labs™. Cura is the foremost provider of premium cannabis oil and hemp oil to the legal domestic and worldwide markets.

The production agreement guarantees GB Sciences a set royalty on every gram produced and sold under the agreement. Cura Cannabis Solutions is known as the maker of the Select Oil and Select CBD group of products.

This week, GB Sciences explained that 100 percent of the mother plants in the Company’s Las Vegas cultivation facility are now products of the GB Sciences tissue propagation initiative. A mother plant is a plant that in its vegetative state does not produce flowers but only branches and leaves.

Dr. Ulrich Reimann-Philipp, Chief Botanist at GB Sciences, said, "Tissue culture propagation is the next wave in the production of pure medical grade Cannabis at commercial scale. GB Sciences is proud to be at the forefront of this movement. R&D in all facets of the Cannabis industry is in our corporate DNA, and we use every means possible to explore and innovate the absolute best methods for turning Cannabis into medicine."

GB Sciences, Inc. (GBLX), closed Friday's trading session at $0.565, up 23.09%, on 6,947,336 volume with 1,988 trades. The average volume for the last 60 days is 775,194 and the stock's 52-week low/high is $0.21/$0.56.


The QualityStocks
Company Corner


Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.25, up 15.74%, on 1,208,480 volume with 1,296 trades. The stock’s average daily volume over the past 60 days is 253,591 and its 52-week low/high is $0.1999/$1.13.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (OTCQB:LXRP), a client of NNW that has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The publication, titled, “Merger and Acquisition Activity is Heating Up in the Cannabis Industry,” discusses acquisitions in the cannabis industry, and several reps making innovative contributions to cannabis product development. To view the full publication, visit: https://www.networknewswire.com/merger-acquisition-activity-heating-cannabis-industry/

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication on M&A Action in the Cannabis Industry

Merger and Acquisition Activity is Heating Up in the Cannabis Industry

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Offers a Sweet Escape for Cannabis Users without Smoking or Sweeteners

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.6239, off by 0.18%, on 163,963 volume with 128 trades. The stock’s average daily volume over the past 60 days is 112,723 and its 52-week low/high is $0.171/$0.77.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to announce the hiring of Dr. M. Scott Alexander as the Company’s Medical Director. He will ensure the medical integrity of Cannevert Therapeutics Ltd. cannabis research programs and develop the medical affairs strategy to support their cannabis strains currently in preclinical and clinical development.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Hires Medical Director to Advise Physicians & Regulators on the Application of Cannevert’s Experimental Results with Cannabis to Clinical Practice & Public Policy

Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

NetworkNewsWire Announces Publication on Investment Opportunities Created by Ongoing R&D of Medical Cannabis

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.9537, off by 7.25%, on 192,418 volume with 169 trades. The stock’s average daily volume over the past 60 days is 107,584, and its 52-week low/high is $0.3148/$1.3041.

First Cobalt Corp. (TSX-V: FCC, ASX: FCC, OTCQB: FTSSF) (the "Company") is pleased to announce it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (collectively, the "Underwriters") pursuant to which they have agreed to purchase, on a bought deal private placement basis, (i) an aggregate of 4,700,000 units of the Company ("Flow-Through Units") at a price of $1.51 per Flow-Through Unit for gross proceeds of $7,097,000 (the "FT Offering") and (ii) an aggregate of 16,400,000 units (the "Units") of the Company at a price of $1.10 per Unit for gross proceeds of $18,040,000 (the "Offering").

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt Announces $25 Million Bought Deal Private Placement Financing

First Cobalt Reports 3.9% Cobalt in Kerr Lake Area

Uptick Newswire “Stock Day” Interviews CEO on First Cobalt’s 2017 Success in the Cobalt Industry

Carl Data Solutions Inc. (CSE:CRL) (FSE:7C5) (OTC:CDTAF)

The QualityStocks Daily Newsletter would like to spotlight Carl Data Solutions Inc. (CDTAF). Today, Carl Data Solutions Inc. closed trading at $0.3134, off by 12.21%, on 732,471 volume with 254 trades. The stock’s average daily volume over the past 60 days is 36,485 and its 52-week low/high is $0.2015/$0.4766.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Carl Data Solutions, Inc. (CSE:CRL) (FSE:7C5) (OTC:CDTAF), a client of NNW and an Industrial IoT (IIoT) company focused on providing next generation information collection, storage and analytics solutions for data-centric companies. The publication, titled, “The Future’s Next Mega-Trend is Here as Smart Companies Embrace the Industrial Internet of Things,” reviews the potential of IoT to impact efficiency across a wide range of sub-sectors. To view the full publication, visit: https://www.networknewswire.com/futures-next-mega-trend-smart-companies-embrace-industrial-internet-things/

Carl Data Solutions Inc. (CSE: CRL) (FSE: 7C5) (OTC: CDTAF), a developer of Big-Data-as-a-Service ("BDaaS")-based solutions for data integration, business intelligence and Industrial Internet-of-Things ("IIoT") applications, is headquartered in Vancouver, British Columbia, Canada. The company's BDaaS enterprise applications platform provides custom cloud-based collection, storage, monitoring and advanced analysis of any data source of any size or complexity.

Carl Data Solutions provides smart, real-time solutions for industries that routinely face an overload of data. The company's team of dedicated data scientists and application developers build environmental monitoring and modeling technology that collects, connects and manages data to protect industrial and infrastructure assets. As experts in data collection, storage, analytics and reporting, the team is experienced in the complex issues facing governmental and industrial sectors and is well positioned in key IIoT market segments to offer customized solutions.

Among the benefits of CARL's Big Data solutions: turning vast quantities of information into meaningful, actionable insights for any business; gathering data from multiple sources and monitoring in real-time, allowing for better decision making and forecasting; identifying business performance issues or operational efficiencies quickly and accurately for cost and time savings; and, mitigating risks with predictive analytic capabilities to manage unplanned events.

The company's most recent acquisitions include:

  • FlowWorks, a SaaS-based monitoring, data collection, alarming, modeling and reporting system utilized by major clients across North America.
  • abEmbedded Systems Ltd., a Mesh and LoRa advanced telemetry platform using industrial grade custom sensors and data loggers operating in over 250 pump stations across North America.
  • Extend to Social (ETS), a social media application that adds a deep analytics layer that provides clients with valuable insights for new marketing campaigns plus behavioral characteristics for customer service, operations and product development.

Carl Data Solutions provides scalable solutions that integrate public data, Smart IIoT and legacy devices that provides real-time alarming and data analysis. Development of a framework that manages large volumes of diverse types of both structured and unstructured data, stored in an unlimited cloud-based platform that offers advanced analytics features for deeper data insights, provides instant analysis of any inbound data. CARL's applications locate relationships and patterns, which can then predict the probability of specific events, providing valuable insights applicable to any entity dealing with operational issues and regulatory requirements. Both technical and business users are able to quickly and easily understand the impact of environmental events on infrastructure through a comprehensive suite of dashboards, geographic information systems and graphic tools.

The company's predictive analytics, machine learning, and web-based applications can be utilized for waste and storm water management, in the protection of oil and gas pipeline stream crossings, and by hydro-electric dams and toxic tailing ponds, among other industrial uses. The global industrial IoT market alone is expected to reach USD $933.62 billion by 2025, according to a new report by Grand View Research, Inc. (http://nnw.fm/yLBv0). Businesses are seeking new operating models that will increase overall productivity, enhance operational efficiency, improve visibility and reduce complexities of various processes – all of which are targets of Carl's Data Solutions.

An expert management team is at the company core with Greg Johnston leading as its president, CEO and director. Johnston is an experienced technology professional with a proven track record of leadership success within both large multinational corporations and small start-up technology ventures. Disclaimer

Carl Data Solutions Inc. Blog

Carl Data Solutions Inc. News:

NetworkNewsWire Announces Publication Featuring IoT Solutions for Critical Protection of Data and Assets

Carl Data Solutions Signs LOI for Acquisition of Cryptocurrency Mining Hardware and Partnership for IIoT BlockChain Technology Development

Carl Data Solutions Signs Letter of Intent for Solid Waste Management Pilot

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0585, off by 41.50%, on 48,216,860 volume with 2,914 trades. The stock’s average daily volume over the past 60 days is 6,643,810, and its 52-week low/high is $0.009/$0.16.

CannabisNewsWire (“CNW”), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring Global Payout, Inc. (OTC:GOHE), a client of CNW and leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. The publication, titled, “Success of Initial Coin Offerings (ICOs) Shows Increasing Application of Blockchain Technology to Payment Solutions,” discusses the development of innovative payment solutions for the underserved cannabis industry. To view the full publication, visit: https://www.cannabisnewswire.com/success-initial-coin-offerings-icos-shows-increasing-application-blockchain-technology-payment-solutions/

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

CannabisNewsWire Announces Publication on Various Applications of Blockchain Technology

MoneyTrac Technology, Inc. Secures Revenue Opportunity with Definitive Referral and Consultant Partnership Agreement with GreenRush Group, Inc.

Bitcoin’s Rise Solidifies the Intersection of Cannabis and Cryptocurrency

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.425, up 3.39%, on 28,686 volume with 10 trades. The stock’s average daily volume over the past 60 days is 34,449 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. (ORHB) Provides 2017 Business Highlights and Sets Special Warrant Exercise Price

ORHub, Inc. (ORHB) Signs 5-year Revenue Agreement with Nationally Recognized "Top 100" Hospital

ORHub, Inc. (ORHB) Warrants Set to Expire on December 31, 2017


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.1199, up 4.66%, on 199,685 volume with 209 trades. The stock’s average daily volume over the past 60 days is 431,512 and its 52-week low/high is $0.6171/$1.42.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Announces Financial Results and Provides Operational Update

NetworkNewsWire Announces Publication on Investment Capital Pouring into Canada's Legal Cannabis Market

Outsized Demand in Canada’s Cannabis Market Triggers Upswing in Smart Money Flowing North


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(MOBQ) +66.67%


Stock Beast
(GLBR) +55.56%


(ICIZF) +44.44%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251